3H-1,4-Benzodiazepine | 264-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3H-1,4-Benzodiazepine
• CAS: 264-65-3
• 化学式: C₉H₈N₂
• 分子量: 144.17
• InChiKey: QQUIWIVTEWQHKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  24.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20170158680A1

  公开（公告）日：2017-06-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由公式（I）表示的杂环化合物，其立体异构体，或其药用可接受的盐，其药物组合物，以及它们用于制备预防或治疗中枢神经系统疾病的药物。
• AROMATIC IMIDE COMPOUND AND METHOD FOR PRODUCING SAME
  申请人：AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L.

  公开号：US20150299132A1

  公开（公告）日：2015-10-22

  [Problem] to provide an aromatic imide compound wherein the sensitivity for visible light such as g-line, h-line etc. is increased and solubility is also improved. [Means for solving problem] The aromatic imide compound of the invention is a compound represented by the formula (1) below (in the formula, R 1 represents a haloalkyl group having 1 to 7 carbon atoms or a haloaryl group, R 2 represents a group containing a substituted or unsubstituted, aliphatic or aromatic group which may have a heteroatom, and adjacent R 2 s may form an imido group by connecting each other, R 3 represent a halogen atom or a hydrocarbon group, m is zero or an integer of 1 or more, n is zero or an integer of 1 or more, and a sum of n and m is 1 to 6). These compounds are obtained by following processes. A halogenated naphtharic anhydride is reacted with an aromatic group-containing hydrocarbon such as ethynylbenzene to prepare a naphthalic anhydride substituted by an aromatic group-containing group. The obtained compound is then reacted with hydroxylamine hydrochloride to be made N-hydoxyimidization. Finally, the resultant compound is reacted with a sulfonyl halide such as trifluoromethylsulfonyl chloride to obtain the objective compound.

  [问题] 提供一种芳香酰亚胺化合物，其中对于可见光如g线、h线等的敏感性增加，溶解度也得到改善。 [解决问题的方法] 本发明的芳香酰亚胺化合物是以下式(1)所表示的化合物(在该式中，R1表示具有1至7个碳原子的卤代烷基或卤代芳基，R2表示含有取代或未取代的脂肪族或芳香族基团，该基团可能具有杂原子，相邻的R2可以通过连接形成亚胺基团，R3表示卤素原子或碳氢基团，m为0或1或更多的整数，n为0或1或更多的整数，n和m的总和为1至6)。这些化合物是通过以下过程获得的。将卤代萘酐与含芳香族基团的烃类化合物如乙炔基苯反应，制备出被芳香族基团取代的萘酐。然后将获得的化合物与盐酸羟胺反应，得到N-羟基亚胺。最后，将所得化合物与三氟甲磺酰卤如三氟甲磺酰氯反应，得到目标化合物。
• HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF
  申请人：Shanghai Institute Of Materia Medica Chinese Academy of Sciences

  公开号：EP3115361A1

  公开（公告）日：2017-01-11

  Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation of a drug for the prevention and/or treatment of a central nervous system disease.

  本发明提供了由式（I）代表的杂环化合物、所述化合物的立体异构体或药学上可接受的盐、所述化合物的药物组合物，以及所述化合物在制备预防和/或治疗中枢神经系统疾病的药物中的应用。
• COMPOUND, POLYMERIZABLE COMPOUND, MIXTURE, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICAL FILM, OPTICALLY ANISOTROPIC PRODUCT, POLARIZING PLATE, FLAT PANEL DISPLAY DEVICE, ORGANIC ELECTROLUMINESCENCE DISPLAY DEVICE, AND ANTI-REFLECTION FILM
  申请人：Zeon Corporation

  公开号：EP3246306A1

  公开（公告）日：2017-11-22

  Disclosed is a mixture containing polymerizable compounds having Formulas (III) and (IV) wherein Ar1 and Ar2 are divalent aromatic hydrocarbon or heteroaromatic ring group having D1 or D2 as a substituent; D1 and D2 are C1-C20 organic group having at least one aromatic ring selected from the group consisting of aromatic hydrocarbon ring and heteroaromatic ring; A11-A22 and B11-B22 are alicyclic or aromatic group which may have a substituent, Y11-Y22 and L11-L22 are single bond, -O-, -CO-, -CO-O-, -O-CO-, -NR21-CO-, -CO-NR22-, -O-CO-O-, -NR23-CO-O-, -O-CO-NR24- or -NR25-CO-NR26- where R21-R26 are hydrogen or C1-C6 alkyl group; R4-R9 are hydrogen, methyl group or chlorine; one of f and k is integer of 1 to 3 with the other being integer of 0 to 3; g, j, m and q are integer of 1 to 20; and h, i, n and p are 0 or 1.

  本发明公开了一种混合物，其中含有具有式（III）和式（IV）的可聚合化合物，其中 Ar1 和 Ar2 是二价芳香烃或杂芳环基团，具有 D1 或 D2 作为取代基；D1 和 D2 是 C1-C20 有机基团，具有至少一个从芳香烃环和杂芳环组成的组中选出的芳香环；A11-A22和B11-B22是脂环族或芳香族基团，可带有取代基；Y11-Y22和L11-L22是单键、-O-、-CO-、-CO-O-、-O-CO-、-NR21-CO-、-CO-NR22-、-O-CO-O-、-NR23-CO-O-、-O-CO-NR24-或-NR25-CO-NR26-，其中R21-R26是氢或C1-C6烷基；R4-R9为氢、甲基或氯；f 和 k 中的一个为 1 至 3 的整数，另一个为 0 至 3 的整数；g、j、m 和 q 为 1 至 20 的整数；h、i、n 和 p 为 0 或 1。
• Heterocyclic compounds, process for preparation of the same and use thereof
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US10174011B2

  公开（公告）日：2019-01-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由式（I）代表的杂环化合物、其立体异构体或其药学上可接受的盐、其药物组合物，以及它们在制备预防和/或治疗中枢神经系统疾病的药物中的用途。